<i>In vitro</i> characteristics of intact and modified MAbs.

aThe data presented is the average of two to five replicates of duplicate measures. bThe data presented is the average of two to four replicates of duplicate measures. c“In vivo therapeutic outcome” refers to lethal, virus-only DENV2 D2S10 challenge or mouse anti-DENV1-enhanced DENV2 D2S10 infection (ADE). d“NN” indicates that the MAb did not neutralize DENV2 D2S10. e“NB” indicates that the MAb did not bind to DENV2 D2S10 by direct capture ELISA. f“ND” indicates that the avidity for MAb 4G2 was not tested via direct capture ELISA. g“ND” indicates that the therapeutic efficacy for these MAbs was not assessed under the conditions specified in footnote “c”.